Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology

Translate this page into:
[gtranslate]

Studies
2004:70:6;353-356
PMID: 17642662

The effect of thyroid hormones in psoriasis vulgaris

Ozer Arican1 , Kaan Bilgic2 , Kadriye Koc3
1 Departments of Dermatology, Kahramanmaras Sutcuimam University, Kahramanmaras, Turkey
2 Boyabat Hospital, Sinop, Turkey
3 Haseki Education and Research Hospital Istanbul, Turkey

Correspondence Address:
Ozer Arican
Sehit Abdullah Cavus M. Alparslan Turkes Bulvari Gulsaray A. B Blok K:3 D:6 Kahramanmaras
Turkey
How to cite this article:
Arican O, Bilgic K, Koc K. The effect of thyroid hormones in psoriasis vulgaris. Indian J Dermatol Venereol Leprol 2004;70:353-356
Copyright: (C)2004 Indian Journal of Dermatology, Venereology, and Leprology

Abstract

BACKGROUND AND AIMS: Certain endocrinological disturbances are assumed to exacerbate psoriasis. In this study we compared the serum thyroid hormone levels of a group of psoriasis patients with that of a control group. METHODS: The total T3 (TT3), free T3 (FT3), total T4 (TT4), free T4 (FT4) and TSH levels obtained from the sera of 103 psoriatics (37 males and 66 females) and 96 controls (40 male and 56 female) were measured by immunological assay. RESULTS: Statistical assessments displayed no differences in TT3, FT4 and TSH serum levels for the two groups. Differences between the means of serum TT4 (P=0.033) and serum FT3 (P=0.041) levels showed statistical differences among the groups. We also found that at least one thyroid hormone level in the blood was increased in 23 patients of the psoriatic group compared to 9 patients in the control group (P=0.022). The average Psoriasis Area and Severity Index scores in this patient group were significantly higher than in those with normal hormone levels (P<0.001). CONCLUSIONS: The role of thyroid hormones in the etiopathogenesis of psoriasis and the effects of such differences in psoriatic patients must be investigated with wider and comprehensive laboratory and clinical studies.
Keywords: T3, T4, TSH, Psoriasis area severity index (PASI)

INTRODUCTION

Psoriasis is a common, chronic relapsing skin disease.[1] Certain endocrinological disturbances exacerbate the disease.[2] An improvement in psoriasis was reported in a psoriatic with hyperthyroidism.[3] It was shown that two thyroid hormones, T3 and T4, cause an increase in Epidermal Growth Factor (EGF) which leads to epidermal hyperplasia.[4] In two different studies Safet et al reported that T3 stimulates the proliferation of keratinocytes.[5],[6]

We compared the levels of thyroid hormones a group of patients with psoriasis vulgaris with those of a control group. We also correlated the PASI (Psoriasis Area and Severity Index) scores in the psoriasis group with serum levels of thyroid hormones.

METHODS

Consecutive patients with psoriasis who had not received any prior treatment within one month were included in the study. Exclusion criteria were psoriatics or controls with known thyroid impairment; those on thyroid hormone, anti-thyroid drugs or other drugs affecting thyroid function, such as lithium, iodine, steroids, dopamine, anticonvulsant drugs, and interferon (which interferes with thyroid hormone level estimation); those who have undergone thyroidectomy; pregnant women and children aged less than 12 years. Patients with erythrodermic, pustular and only palmoplantar forms of psoriasis were also excluded. The control group was comprised of randomly selected patients from our clinic having skin diseases other than psoriasis.

Blood samples were collected on empty stomach between 08:30-10:30 hours. Measurements were carried out by using total T3 (TT3), free T3 (FT3), total T4 (TT4), free T4 (FT4) and TSH (Thyroid Stimulating Hormone) Immulite 2000 kits with the aid of an immunometric assay method. The severity of psoriasis was assessed by the PASI score for each patient.

Statistical assessment was done by using the SPSS 10.0 for Windows. Unpaired t-test was used when comparing mean values between groups. Chi-square test was used when comparing differences between the frequencies. A significance level of P Value < 0.05 was chosen.

RESULTS

A total number of 103 psoriatics (37 males and 66 females), and 96 controls (40 males and 56 females) were included in the study. The age of patients in the psoriasis group ranged from 16 to 79 (mean: 38.03 ± 21.48) years and 14 to 90 (mean: 34.16 ± 19.66) years in the control group. There was no statistical difference between the groups in terms of sex (P=0.406) and distribution of age (P=0.184). The duration of disease in the patient group ranged from 1 month to 65 years (mean: 11.02 ± 13.18 years).

The serum values of different thyroid hormones of both groups are shown in [Table - 1]. On comparing both groups, the mean values of only FT3 and TT4 show a statistically significant difference (P< 0.05). At least one thyroid hormone level in blood was increased in 23 (22.33%) patients of the psoriatic group as compared to 9 (9.37%) patients in the control group (P=0.022). The average PASI score in those 23 patients [10.99 ± 5.01 (4.9-22.5)] was relatively higher than that of patients in the psoriatic group having normal hormone levels [6.24 ± 3.46 (1.4-15.5)]. This difference in the average PASI scores between those two groups was statistically significant (P< 0.001).

DISCUSSION

In spite of the fact that many developments are recorded in the treatment and pathogenesis of psoriasis, its etiology still remains obscure. Propylthiouracil, an anti-thyroid preparation, was successfully used both in local[7] and systemic[8],[9],[10] treatment of psoriasis. Although the mechanism of action was unclear, it was suggested that this drug might have a regulatory effect on the T cells in the psoriasis plaque.[9],[10] Propylthiouracil increased the number of total and suppressor/cytotoxic T cells and reduced activated lymphocytes in psoriatic plaques.[10] Other anti-thyroid agents, such as methimazole[11] and thiamazole,[12] have also been used successfully in the treatment of psoriasis. This means that thyroid hormones may have unknown effects on the disease.

It is postulated that T3 receptors may play a role in the synthesis of keratin.[8] The existence of T3 receptors on the skin was also proved.[13] Propylthiouracil, which is known to be an anti-thyroid drug, may affect the keratin synthesis process by binding to nuclear T3 receptors.[14] It is also known that T3 has a major role in the regulation of cell growth and differentiation.[15],[16] Moreover, it has been stated that T3 and T4 have hyperproliferative effect on the skin by EGF.[4]

In this study the serum TT4 and FT3 levels were significantly higher in psoriatics than in the control group. The average PASI scores were significantly higher in these patients and this may be due to the direct or indirect effects of thyroid hormones on the course of psoriasis. Thus excessive production of thyroid hormones may aggravate psoriasis.

The skin may be a target organ for thyroid hormones and these hormones increase EGF and therefore accelerate epidermal proliferation.[5],[17] The role of these hormones on the etiopathogenesis of psoriasis will become clearer when the effect of thyroid hormones on keratinocytes and the anti-proliferative effect of anti-thyroid drugs on psoriasis are better demonstrated with experimental studies. Meanwhile, it may be useful to check the thyroid function in patients with uncontrolled and relapsing psoriasis.

References
1.
Cristophers E, Mrowietz U. Psoriasis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's Dermatology in General Medicine, 5th Ed. New York: McGraw-Hill; 1999. p. 495-521.
[Google Scholar]
2.
Tagami H. Triggering factors. Clin Derm 1997;15:677-85.
[Google Scholar]
3.
Humphreys MS, Waddell JL. Lithium, psoriasis, abnormal glucose tolerance and thyroid dysfunction. Br J Psychiatry 1988;152:437-8.
[Google Scholar]
4.
Hoath SB, Lakshmanan J, Scott SM, Fisher DA. Effect of thyroid hormones on epidermal growth factor concentration in neonatal mouse skin. Endocrinology 1983;112:308-14.
[Google Scholar]
5.
Safer JD, Fraser LM, Ray S, Holick MF. Topical triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. Thyroid 2001;11:717-24.
[Google Scholar]
6.
Safer JD, Crawford TM, Fraser LM, Hoa M, Ray S, Chen TC, et al. Thyroid hormone action on skin: Diverging effects of topical versus intraperitoneal administration. Thyroid 2003;13:159-65.
[Google Scholar]
7.
Elias AN, Dangaran K, Barr J, Rohan K, Goodman MM. A controlled trial of topical propylthiouracil in the treatment of patients with psoriasis. J Am Acad Dermatol 1994;31:455-8.
[Google Scholar]
8.
Elias AR, Barr RJ. Low dose oral propylthiouracil in the treatment of plaque psoriasis. Int J Dermatol 1995;34:519-20.
[Google Scholar]
9.
Elias AN, Goodman MM, Liem WH, Barr J. Propylthiouracil in psoriasis: Result of an open trial. J Am Acad Dermatol 1993;29:78-81.
[Google Scholar]
10.
Chowdhury MM, Marks R. Oral propylthiouracil for the treatment of resistant plaque psoriasis. J Dermatol Treat 2001;12:81-5.
[Google Scholar]
11.
Elias AN, Goodman MM, Rohan MK, Alpern K, Barr RJ. Methimazole in psoriasis: Results of an open trial. Dermatology 1993;187:26-9.
[Google Scholar]
12.
Abe M, Ohnishi K, Hasegawa M, Aoyama K, Tamura A, Kan C, et al. The antipsoriatic effect of thiamazole is not accompanied either by significant changes in blood lymphocyte subsets nor by serum concentration of TNF-alpha. Eur J Dermatol 2002;12:335-9.
[Google Scholar]
13.
Ribeiro RC, Apriletti JW, West BL, Wagner RL, Fletterick RJ, Schaufele F, et al. The molecular biology of thyroid hormone action. Ann N Y Acad Sci 1995;758:366-89.
[Google Scholar]
14.
Takagi S, Hummel BC, Walfish PG. Thionamides and arsenite inhibit T[3] binding to hepatic nuclear receptor. Biochem Cell Biol 1990;68:616-21.
[Google Scholar]
15.
Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ. A structural role for hormone in the thyroid hormone receptor. Nature 1995;378:690-7.
[Google Scholar]
16.
Torma H, Rollman O, Vahlquist A. Detection of mRNA transcripts for retinoic acid, vitamin D3, and thyroid hormone (c-erb-A) nuclear receptors in human skin using reverse transcription and polymerase chain reaction. Acta Derm Venereol 1993;73:102-7.
[Google Scholar]
17.
Hoath SB, Lakshmanan J, Fisher DA. Epidermal growth factor binding to neonatal mouse skin explants and membrane preparations - effect of triiodothyronine. Pediatr Res 1985;19:277-81.
[Google Scholar]
Show Sections